Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04372576|
Recruitment Status : Recruiting
First Posted : May 4, 2020
Last Update Posted : May 4, 2020
|Condition or disease||Intervention/treatment|
|Ventilator Associated Pneumonia Corona Virus Infection||Diagnostic Test: Assessment of ventilator-associated pneumonia criteria|
Coronavirus Disease 2019 (CoViD-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic affecting thousands of individuals worldwide. A considerable proportion of CoViD-19 patients require admission to the intensive care unit (ICU), although limited data are available on their clinical characteristics and course. The results of retrospective studies indicate older age, presence of comorbidies and secondary infections as predictors of mortality among this population. Further evaluation regarding ICU clinical course and predictors of mortality is needed.
The aim of this study is to determine the risk factors for development of VAP and to identify the prognostic factors of VAP among CoViD-19 patients.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients|
|Actual Study Start Date :||April 16, 2020|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||August 2020|
- Diagnostic Test: Assessment of ventilator-associated pneumonia criteria
Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
- 28-day all-cause mortality [ Time Frame: at study completion, anticipated 5 months ]
- Days of mechanical ventilation [ Time Frame: average time frame expected 2-3 weeks ]
- ICU length-of-stay [ Time Frame: average time frame expected 3-4 weeks ]
- Antibiotic utilization [ Time Frame: average time frame expected 3-4 weeks (at discharge from ICU) ]
- Ventilator-associated pneumonia rate [ Time Frame: at study completion, anticipated 5 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04372576
|Budapest, Hungary, 1085|
|Contact: Bence Mogyoródi, MD +36208250801 firstname.lastname@example.org|